Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma

PurposeIn patients with follicular lymphoma, secondary transformation to aggressive lymphoma (tFL) implies a poor prognosis. In principle, allogeneic haematopoietic cell transplantation (allo-HCT) offers a chance of cure for tFL but is rarely practiced. Aim of this retrospective multicenter study wa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Heinzelmann, Frank (VerfasserIn) , Bethge, Wolfgang Andreas (VerfasserIn) , Beelen, Dietrich W. (VerfasserIn) , Stelljes, Matthias (VerfasserIn) , Dreger, Peter (VerfasserIn) , Engelhard, Marianne (VerfasserIn) , Finke, Jürgen (VerfasserIn) , Kröger, Nicolaus (VerfasserIn) , Holler, Ernst (VerfasserIn) , Bornhäuser, Martin (VerfasserIn) , Müller, Annerose (VerfasserIn) , Haubitz, Imme (VerfasserIn) , Ottinger, Hellmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: June 2018
In: Journal of cancer research and clinical oncology
Year: 2018, Jahrgang: 144, Heft: 6, Pages: 1173-1183
ISSN:1432-1335
DOI:10.1007/s00432-018-2633-5
Online-Zugang:Verlag, Volltext: https://doi.org/10.1007/s00432-018-2633-5
Volltext
Verfasserangaben:Frank Heinzelmann, Wolfgang Bethge, Dietrich Wilhelm Beelen, Matthias Stelljes, Peter Dreger, Marianne Engelhard, Jürgen Finke, Nikolaus Kröger, Ernst Holler, Martin Bornhäuser, Annerose Müller, Imme Haubitz, Hellmut Ottinger
Beschreibung
Zusammenfassung:PurposeIn patients with follicular lymphoma, secondary transformation to aggressive lymphoma (tFL) implies a poor prognosis. In principle, allogeneic haematopoietic cell transplantation (allo-HCT) offers a chance of cure for tFL but is rarely practiced. Aim of this retrospective multicenter study was to define the actual significance of allo-HCT in treatment of tFL.MethodsThe database of the German Registry for Stem Cell Transplantation (DRST) was screened for patients who underwent allo-HCT for tFL 1998-2008. Confirmation of tFL-diagnosis by local and/or pathologists of the National NHL Board was mandatory for enrolment. Gaps in reported EBMT Minimum Essential Data datasets (MED-A) were filled by local DRST data managers. Relevant HCT outcome variables were evaluated by uni- and multivariate statistical analysis.ResultsMedian age of enrolled 33 patients was 51 years with a post allo-HCT median follow-up of 7.1 years of surviving patients. At time of HCT 24/33 patients had chemosensitive disease. In 24/33 patients reduced intensity conditioning (RIC) was used. Estimated 1, 2, 5-year overall survival (OS) and event-free survival rates were 49/39/33, and 33/30/24%. Cumulative 100 days non-relapse mortality was 25%. Chemosensitive disease, RIC, and limited chronic GvHD were identified as independent prognostic factors for OS.ConclusionsAllo-HCT offers the chance of cure for tFL.
Beschreibung:Gesehen am 24.09.2019
Beschreibung:Online Resource
ISSN:1432-1335
DOI:10.1007/s00432-018-2633-5